Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three chemotherapy drugs: doxorubicin (also known as Adriamycin), vinblastine, and dacarbazine. Each drug has a distinct mechanism of action targeting rapidly dividing cancer cells. Doxorubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. Vinblastine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and arresting cell division at metaphase. Dacarbazine is an alkylating agent that methylates guanine in DNA, resulting in inhibition of DNA synthesis and function[1][4][5][6]. This combination is primarily used for the treatment of Hodgkin lymphoma but may also be considered for other cancers such as melanoma or sarcoma when part of multi-drug regimens[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on doxorubicin + vinblastine + dacarbazine.